Indication

In combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

Medicine details

Medicine name:
avelumab (Bavencio)
SMC ID:
SMC2248
Pharmaceutical company
Merck
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
12 October 2020
SMC meeting date:
01 September 2020
Patient group submission deadline:
03 February 2020